专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2004094673A8 METHODS FOR MONITORING DRUG ACTIVITIES IN VIVO 审中-公开
标题翻译：监测体内药物活性的方法
公开(公告)号：WO2004094673A8
公开(公告)日：2004-12-23
申请号：PCT/US2004006601
申请日：2004-03-05
申请人： WYETH CORP , BURCZYNSKI MICHAEL E , BONI JOSEPH , FITZPATRICK VIRGINIA , TWINE NATALIE C , STOVER JENNIFER , DORNER ANDREW , IMMERMAN FRED , TREPICCHIO WILLIAM
发明人： BURCZYNSKI MICHAEL E , BONI JOSEPH , FITZPATRICK VIRGINIA , TWINE NATALIE C , STOVER JENNIFER , DORNER ANDREW , IMMERMAN FRED , TREPICCHIO WILLIAM
IPC分类号： A61K38/17 , C07K16/18 , C12N20060101 , C12Q1/68 , G01N33/53 , G01N33/567
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/158
摘要： Methods, systems and equipment useful for monitoring in vivo activities of CCI-779 or other drugs. Numerous drug activity genes can be identified by the present invention. The expression profiles of these genes in peripheral blood mononuclear cells are modulateable by CCI-779 or other drugs. Therefore, these genes can be used as surrogate markers for detecting or monitoring drug activities in vivo.
摘要翻译：用于监测CCI-779或其他药物的体内活性的方法，系统和设备。许多药物活性基因可以通过本发明来鉴定。这些基因在外周血单核细胞中的表达谱可由CCI-779或其他药物调节。因此，这些基因可以用作检测或监测体内药物活性的替代标记。

2. 发明申请

WO2006089312A3 ORALLY BIOAVAILABLE CCI-779 TABLET FORMULATIONS 审中-公开
标题翻译： ORILEY BIOAVAILABLE CCI-779 TABLET配方
公开(公告)号：WO2006089312A3
公开(公告)日：2006-10-19
申请号：PCT/US2006006991
申请日：2006-02-13
申请人： WYETH CORP , BONI JOSEPH P , ASHRAF MUHAMMAD , BANJAMIN ERIC J
发明人： BONI JOSEPH P , ASHRAF MUHAMMAD , BANJAMIN ERIC J
IPC分类号： A61K9/20 , A61K9/48 , A61K31/4745
CPC分类号： A61K9/2095 , A61K9/146 , A61K9/2027 , A61K31/4745
摘要： A CCI-779 oral dosage form is provided in which, after oral administration to a subject, the CCI-779 has a whole blood peak concentration (C max ) of 5.4 ± 1.8 ng/mL and an area under the curve (AUC) of about 66 ± about 22 ng-hr/ml and the sirolimus has a C max of 18.7 ± 9.6 ng/mL and an AUC of about 600 ± about 228 ng- hr/ml, for a 25 mg unit dose of CCI-779-Products containing these oral dosage forms, and methods of use thereof, are also described.
摘要翻译：提供CCI-779口服剂型，其中口服给予受试者后，CCI-779具有5.4±1.8ng / mL的全血峰浓度（C max）和面积在约66±约22ng-hr / ml的曲线（AUC）下，西罗莫司的C max最大值为18.7±9.6ng / mL，AUC为约600±约228ng-小时 / ml，对于25mg单位剂量的含有这些口服剂型的CCI-779-产品及其使用方法也被描述。

3. 发明申请

WO2006089312A2 ORALLY BIOAVAILABLE CCI-779 FORMULATIONS 审中-公开
标题翻译： ORALY BIOAVAILABLE CCI-779配方
公开(公告)号：WO2006089312A2
公开(公告)日：2006-08-24
申请号：PCT/US2006/006991
申请日：2006-02-13
申请人： WYETH , BONI, Joseph, P. , ASHRAF, Muhammad , BANJAMIN, Eric, J.
发明人： BONI, Joseph, P. , ASHRAF, Muhammad , BANJAMIN, Eric, J.
CPC分类号： A61K9/2095 , A61K9/146 , A61K9/2027 , A61K31/4745
摘要： A CCI-779 oral dosage form is provided in which, after oral administration to a subject, the CCI-779 has a whole blood peak concentration (C max ) of 5.4 ± 1.8 ng/niL and an area under the curve (AUC) of about 66 ± about 22 ng-hr/ml and the sirolimus has a C max of 18.7 ± 9.6 ng/mL and an AUC of about 600 ± about 228 ng- hr/ml, for a 25 mg unit dose of CCI-779. Another CCI-779 oral dosage form is provided which, after oral administration thereof to a subject, the CCI-779 has a C max of 5.7 ± 1.7 ng/mL and an AUC of about 60 ± about 20 ng-hr/ml and the sirolimus has a C max of 17.1 ± 8.1 ng/mL and an AUC of about 548 ± about 187 ng-hr/ml in whole blood, for a 25 mg unit dose of CCI-779. Products containing these oral dosage forms, and methods of use thereof, are also described.
摘要翻译：提供CCI-779口服剂型，其中口服给予受试者后，CCI-779具有5.4±1.8ng / mL的全血峰浓度（C max）和面积在约66±约22ng-hr / ml的曲线（AUC）下，西罗莫司的C max最大值为18.7±9.6ng / mL，AUC为约600±约228ng-小时 / ml，用于25mg单位剂量的CCI-779。提供了另一种CCI-779口服剂型，其在口服给予受试者后，CCI-779的C max≥5.7±1.7ng / mL，AUC为约60±20 ng-hr / ml，并且西罗莫司在全血中的C max最大值为17.1±8.1ng / mL，AUC为约548±约187ng-hr / ml，对于25mg单位剂量的CCI-779。还描述了含有这些口服剂型的产品及其使用方法。

4. 发明申请

WO2004094673A3 METHODS FOR MONITORING DRUG ACTIVITIES IN VIVO 审中-公开
公开(公告)号：WO2004094673A3
公开(公告)日：2004-11-04
申请号：PCT/US2004/006601
申请日：2004-03-05
申请人： WYETH , IMMERMAN, Fred , TREPICCHIO, William , BURCZYNSKI, Michael, E. , BONI, Joseph , FITZPATRICK, Virginia , TWINE, Natalie, C. , STOVER, Jennifer , DORNER, Andrew
发明人： IMMERMAN, Fred , TREPICCHIO, William , BURCZYNSKI, Michael, E. , BONI, Joseph , FITZPATRICK, Virginia , TWINE, Natalie, C. , STOVER, Jennifer , DORNER, Andrew
IPC分类号： C12Q1/68
摘要： Methods, systems and equipment useful for monitoring in vivo activities of CCI-779 or other drugs. Numerous drug activity genes can be identified by the present invention. The expression profiles of these genes in peripheral blood mononuclear cells are modulateable by CCI-779 or other drugs. Therefore, these genes can be used as surrogate markers for detecting or monitoring drug activities in vivo .

5. 发明申请

WO2004094673A2 METHODS FOR MONITORING DRUG ACTIVITIES IN VIVO 审中-公开
标题翻译： VIVO监测药物活动的方法
公开(公告)号：WO2004094673A2
公开(公告)日：2004-11-04
申请号：PCT/US2004006601
申请日：2004-03-05
申请人： WYETH CORP , BURCZYNSKI MICHAEL E , BONI JOSEPH , FITZPATRICK VIRGINIA , TWINE NATALIE C , STOVER JENNIFER , DORNER ANDREW , IMMERMAN FRED , TREPICCHIO WILLIAM
发明人： BURCZYNSKI MICHAEL E , BONI JOSEPH , FITZPATRICK VIRGINIA , TWINE NATALIE C , STOVER JENNIFER , DORNER ANDREW , IMMERMAN FRED , TREPICCHIO WILLIAM
IPC分类号： A61K38/17 , C07K16/18 , C12N20060101 , C12Q1/68 , G01N33/53 , G01N33/567
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/158
摘要： Methods, systems and equipment useful for monitoring in vivo activities of CCI-779 or other drugs. Numerous drug activity genes can be identified by the present invention. The expression profiles of these genes in peripheral blood mononuclear cells are modulateable by CCI-779 or other drugs. Therefore, these genes can be used as surrogate markers for detecting or monitoring drug activities in vivo.
摘要翻译：可用于监测CCI-779或其他药物体内活动的方法，系统和设备。可以通过本发明鉴定许多药物活性基因。这些基因在外周血单个核细胞中的表达谱可以通过CCI-779或其他药物调节。因此，这些基因可以用作体内检测或监测药物活性的替代标记物。

6. 发明专利

CH294001A Procedimento per formare pieghe ingualcibili nella stoffa. 未知
公开(公告)号：CH294001A
公开(公告)日：1953-10-31
申请号：CH294001D
申请日：1951-06-14
申请人： BONI JOSEPH
发明人： JOSEPH BONI
IPC分类号： A41D1/10

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式